In recent years, Boan Biology has stepped up its efforts to effectively promote the global R & D strategy of biological drugs. at present, the R & D process of a number of candidate drugs in the company's innovative R & D pipeline is under intensive progress.

Zhitong Financial APP learned that Green Leaf Pharmaceuticals (02186) announced on October 13 that the application for listing license of Dishumab injection (LY06006 / BA6101) developed by its holding subsidiary Boan Biological had been accepted by the Drug Review Center of the State Drug Administration. This means that another achievement of the company has made phased progress, and LY06006 / BA6101 may become the next landing achievement of Boan biology after bevacizumab injection Boyunol ®.

LY06006 / BA6101 is a human monoclonal antibody against IgG2 and a biological analogue of Prolia ®. By inhibiting the binding of RANKL to its receptor RANK, it reduces the formation, function and survival of osteoclasts, thereby reducing bone resorption, increasing bone mass and improving the strength of cortical or cancellous bone.

Desuzumab injection has a broad market prospect all over the world. According to public financial reports, LY06006/BA6101 's comparable product, Prolia ®, had global sales of $2.76 billion in 2020. In June 2020, Prolia ®was listed in China with the approval of the State Drug Administration.

At present, the indications approved by Prolia ®worldwide include: 1. Treatment of osteoporosis in postmenopausal women with high risk of fracture; 2. Increase the bone mass of male patients with osteoporosis at high risk of fracture; 3. Treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture; 4. increase the bone mass of men at high risk of fracture due to androgen deprivation treatment for non-metastatic prostate cancer; 5. Increase bone mass in women at high risk of fracture for breast cancer treated with aromatase inhibitors.

According to statistics, the progress of LY06006 / BA6101 listing application is in the forefront of China, and its phase I clinical trials in Europe and the United States are also under way. In addition, Boan Biology also plans to register LY06006 / BA6101 in other countries and regions around the world.

Boan Biology is committed to building a diverse product portfolio covering innovative antibodies, bioanalogs, cell therapy and other areas. its research and development pipeline includes more than a dozen innovative antibodies with international intellectual property protection and a range of biosimilar drugs. The company is accelerating the global layout of the biopharmaceutical business in order to provide high-quality biopharmaceutical products to patients around the world and serve the treatment needs that need to be met urgently.